Paola Guglielmelli, MD, PhD

Personal data

Date and place of birth: 27/06/1976, Pistoia (Italy)
Citizenship:Italian

Work address:Hematology Department, University of Florence

L.go Brambilla 3, Florence, Italy

Phone: +39 0557947688

E-mail:

Education

2003:University of Florence, MD degree 110/110 magna cum laude, with a thesis on a haematological subject.

2003-2004: Fellow in the Laboratory for the study of Myeloproliferative Disorders, Hematology Department, University of Florence under the supervision of Professor AM. Vannucchi, working in the field of chronic myeloproliferative neoplasm (MPNs), both clinical and experimental projects

2004-2007: Fellow in the PostgraduateSchool of Hematology , University of Florence

2007: Specialty degree in Hematology, magna cum laude, discussing a thesis on myeloproliferative disorders subject.

2008: Post-doctoral School in Clinical and Experimental Oncology, University of Florence (three years duration)

2010: Researcherscientist in Hematology, University of Florence (three years duration)

Clinical/Research experience

2007: visiting Scientist, INSERM U790, Institute Gustave Roussy (director Dr. William Vainchenker), Villejuif, Parigi.

2007: visiting Scientist, INSERM 602, Institut André LwoffUniversité Paris XI Hôpital Paul Brousse (director Dr. Marie-Caroline Le Bousse-Kerdilès), Villejuif, Parigi.

2010: visiting Scientist, National Genetics Reference Laboratory (Wessex), Salisbury NHS Foundation Trust (Director Professor NCP Cross), Salisbury Wiltshire, UK

Technical skills and competences

My main scientific interests concern experimental and clinical issues of Myeloproliferative Neoplasms (MPNs). I have been working on the molecular characterization of the coding mRNA and microRNA expression profile in hematopoietic cells of patients with MPNs. I have been also involved in the study of a novel animal model of myelofibrosis, the GATA-1low mice. Furthermore, I am strongly committed to clinical work, having in routine charge patients with MPNs and being involved in epidemiologic studies and in clinical protocols with novel drugs.

Grant/Awards

-2006: EC Scholarship for theSecond ESH Euroconference on Myeloproliferative disorders: molecular pathogenesis and therapy

-2006: IX Congresso Nazionale Società Italiana di Ematologia Sperimentale (SIES) Travel Grant

-2007: 12° Congress of the European Hematology Association Travel Grant

-2007: Recipient of the grant “Stage di Formazione in oncologia” promoted by Istituto Tumori Toscano (ITT) for the mobility of researchers.

-2008: X Congresso Nazionale Società Italiana di Ematologia Sperimentale (SIES) Travel Grant

-2009: 51st Annual Meeting of the American Society of Hematology , ASH Travel Award

-2011: Plenary SIES (società italiana diematologia sperimentale) Symposium at the at the 43th National congress of the Italian Society of Hematology (SIE) Naopli 16-19 October 2010

Author of more 60 publications on international scientific journals (ISI h-index=21, G-index=39, mean IF=10.96), chapters of Books and proceedings of international conferences.

Florence, 16/01/2012

LIST OF PUBLICATION - FULL PAPER from 2004-

Papers:63Cites/paper:26.23h-index:21

Citations:1600Cites/author:387.37g-index:39

TOTAL IMPACT FACTPR = 504.349

MEDIA IF = 10.96411

  1. Vannucchi AM, Grossi A, Pancrazzi A, Antonioli E, Guglielmelli P, Balestri F, Biscardi M, Bulgarelli S, Longo G, Graziano C, Gugliotta L, Bosi A. (2004) PRV-1, erythroid colonies, and platelet Mpl are unrelated to thrombosis in essential thrombocythaemia. Brit J Haematol 127:214-219. IF 4.49
  1. Rubegni P, Cuccia A, Sbano P, Cevenini G, Carcagni MR, D'Ascenzo G, De Aloe G, Guidi S, Guglielmelli P, Marotta G, Lauria F, Bosi A, Fimiani M. Role of extracorporeal photochemotherapy in patients with refractory chronic graft-versus-host disease. Br J Haematol. 2005 Jul;130(2):271-5. Erratum in: Br J Haematol. 2005 Sep;130(6):973. Guglielmetti, P [corrected to Guglielmelli, P]. IF 4.49
  1. Antonioli E, Guglielmelli P, Pancrazzi A, Bogani C, Verrucci M, Ponziani V, Longo G, Bosi A, Vannucchi AM (2005) Clinical implication of the JAK2 V617F mutation in essential thrombocythemia. Leukemia, 19:1847-1849. IF 6.612
  1. Sanchez M, Weissman IL, Pallavicini M, Valeri M, Guglielmelli P, Vannucchi AM, Migliaccio G, Migliaccio AR (2006) Differential amplification of murine bipotent megakaryocytic/erythroid “progenitor” and “precursor” cells during recovery from acute and chronic erythroid stress. Stem Cell, 24:337-348. IF 7.924
  1. Vannucchi AM, Guglielmelli P, Antonioli E, Mappa S, Pancrazzi A, Bogani C, Ponziani V, Bosi A (2006) Inconsistencies in the association between JAK2V617F mutation and PRV-1 overexpression among trhe chronic myeloproliferative diseases. British Journal of Haematology 132: 651-61. IF 4.498
  1. Vannucchi AM, Pancrazzi A, Bogani C, Antonioli E, Guglielmelli P. (2006) A quantitative assay for JAK2V617F mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis. Leukemia 20:1055-60. IF 6.146
  1. Ponziani V, Gianfaldoni G, Mannelli F, Leoni F, Ciolli S, Guglielmelli P, Antonioli E, Longo G, Bosi, A, Vannucchi AM (2006) The size of duplication dose not add to the prognostic significance of FLT3 internal tandem duplication in acute myeloid leukemia patients. Leukemia, 20:2074-6. Epub 2006 Aug 31 IF 6.146
  1. Guglielmelli P, Zini R, Bogani C, Salati A, Pancrazzi A, Bianchi E, Mannelli F, Ferrari S, Le Bousse-Kerdiles MC, Bosi A, Barosi G, Migliaccio AR, Manfredini R, Vannucchi AM. (2007) Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms’tumor gene (WT1). Stem Cells 25(1):165-73. Epub 2006 Sep 21 IF 7.531
  1. Bogani C, Guglielmelli P, Antonioli E, Pancrazzi A, Bosi A, Vannucchi AM. B- and T-cell lineage involvement in JAK2V617F-positive idiopathic myelofibrosis patients. (2007) Haematologica, 92:258-9. IF 5.516
  1. Rosti V, Massa M, Vannucchi AM, Bergamaschi G, Campanellli R, Pecci A, Viarengo G, Marchetti M, Guglielmelli P, Xu M, Bruno E, Hoffman R, Barosi G. (2007) The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia. Blood Molecule Cell Disease, 2007 May-Jun;38(3):280-6 IF 2.555
  1. Guglielmelli P, Pancrazzi A, Bergamaschi G, Rosti V, Villani E, Antonioli E, Bosi A, Barosi G and Vannucchi.AM(2007) Anemia characterizes patients with myelofibrosis harbouringMPLw515l/k mutation. British Journal of Haematology, 137:244-247. IF 4.490
  1. Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, Marchioli R, Marfisi RM, Finazzi G, Guerini V, Fabris F, Randi ML, De Stefano V, Caberlon S, Tafuri S, Ruggeri M, Specchia G, Liso V, Rossi E, Pogliani E, Gugliotta L, Bosi A and Barbui T, for the GIMEMA-MPD WP. (2007) Clinical profile of homozygous JAK2 v617f mutation in patients with polycythemia vera or essential thrombocythemia. BLOODEpub March 21; 110:840-846. IF 10.896
  1. Vannucchi AM, Antonioli E, Guglielmelli P, Longo G, Pancrazzi A, Ponziani V, Bogani C, Rossi Ferrini P, Rambaldi A, Guerini V, Bosi A, Barbui T, for the MPD-RC. (2007) Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden. Leukemia 21:1952-1959. IF 6.924
  1. Vannucchi AM, Guidi S, Guglielmelli P, Glinz S, Lombardini L, Busca A, Locatelli F, Dall’Olmo AM, Bosi A. (2007) Significance of CTLA-4 and CD14 genetic polymorphisms in clinical outcome after allogeneic stem cell transplantation. Bone Marrow Transplantation, 40(10):1001-2. Epub 2007 Sep 10 IF 3.000
  1. Guglielmelli P, Tozzi L, Pancrazzi A, Bogani C, Antonioli E, Ponziani V, Poli G, Zini R, Ferrari S, Manfredini R, Bosi A, Vannucchi AM (2007) microRNA expression profile in granulocytes from primary myelofibrosis patients. Experimental Hematology, 35(11):1708-18 IF 3.147
  1. Barosi G, Bergamaschi G, Marchetti M, Vannucchi AM,Guglielmelli P, Antonioli E, Massa M, Rosti V, Campanelli R, Villani L, Viarengo G, Gattoni E, Specchia G, Tinelli C, Barbui T. (2007) JAK2V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. BLOOD, 110(12):4030-6. Epub 2007 Aug 21. IF 10.896
  1. Antonioli E, Guglielmelli P, Poli G, Santini V, Bosi A, Vannucchi AM (2007). Polycythemia Vera after autologous transplantation for AML: insights on the kinetic of JAK2617V>F clonal dominance. BLOOD, 110(13):4620-1. IF 10.896
  1. Bocchia M, Vannucchi AM, Gozzetti A, Guglielmelli P, Poli G, Crupi R, Defina M, Bosi A, Lauria F. (2007) Insights into JAK2-V617F mutation in CML. Lancet Oncology, 2007, 8:864-866. IF 12.247
  1. De Stefano, V., Za, T.,Rossi, E.,Vannucchi, A. M.,Ruggeri, M.,Elli, E.,Mico, C.,Tieghi, A.,Cacciola, R. R.,Santoro, C.,Gerli, G.,Vianelli, N.,Guglielmelli, P.,Pieri, Scognamiglio, F., Rodeghiero, F., Pogliani, E. M.,Finazzi, G.Gugliotta, L.,Marchioli, Leone, G.,Barbui, T. (2008) Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors,and effect of treatments, Haematologica 93:372-380. IF 5.978
  1. De Stefano V, Za T, Rossi E, Elli E, Vannucchi AM, Ruggeri M, Micò C, Vianelli N, Cacciola R, Tieghi A, Santoro C, Pogliani EM, Guglielmelli P, Pieri L, Scognamiglio F, Rodeghiero F, Finazzi G, Gugliotta L, Leone G, Barbui T, for the GIMEMA-MPD WP. (2007) Recurrent venous thrombosis in patients with polycythemia vera and essential thrombocythemia. Clinical Leukemia, 1(6):339-344.
  1. Ponziani V, Mannelli F, Bartalucci N, Gianfaldoni G, Leoni F, Antonioli E, Guglielmelli P, Ciolli S, Bosi A, Vannucchi AM (2008) No role for CXCL12-G801A polymophism in the development of extramedullary disease in acute myeloid leukemia. Leukemia, 22:669-671. IF 8.634
  1. Antonioli E, Guglielmelli P, Poli G, Bogani C, Pacrazzi A, Longo G, Ponziani V, Tozzi L, Pieri L, Santini V, Bosi A, Vannucchi AM. (2008) Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica, 93:41-48. IF 5.978
  1. Pieri L, Guglielmelli P, Bogani C, Bosi A, Vannucchi AM (2008). Mesenchymal stem cells from JAK2V617F mutant patients with primary myelofibrosis do not harbor JAK2 mutant allele. Leukemia Research 32:516-517.IF 2.390
  1. Carobbio A, Antonioli E, Guglielmelli P, Vannucchi AM, Delaini F, Guerini V, Finazzi G, Rambaldi A, Barbui T (2008) Leukocytosis and risk stratification assessment in essential thrombocythemia. Journal of Clinical Oncology, 26: 320 IF 17.157
  1. Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A (2008) Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia 22:1299-1307. IF 8.634
  1. Vannucchi AM, Guglielmelli P (2008) Molecular pathophysiology of Philadelphia-negative myeloproliferative disorders: beyond JAK2 and MPL mutation. Haematologica, 93: 13-16. IF 5.978
  1. Bogani C, Ponziani V, Guglielmelli P, Desterke C, Rosti V, Bosi A, Le Bousse-Kerdiles MC, Barosi G, Vannucchi AM (2008). Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primari myelofibrosis. Stem Cells, 26:1920-1930. IF 7.741
  1. Vannucchi AM, AntonioliE, Guglielmelli P, Pancrazzi A, Guerin V, Barosi G, Ruggeri M, Specchia G, LoCoco F, Delfini F, VillaniL, FiottoS, Ammatuna E, Alterini R, Carrai V, Capaccioli G, Di Lollo S, Liso V, Rambaldi A, Bosi A,Barbui T. (2008) Characteristics And Clinical Correlates of Mpl 515W>L/K Mutation In Essential Thrombocythemia. Blood, 112:844-847. IF 10.432
  1. Carobbio A, Finazzi G, Antonioli E, Guglielmelli P, Vannucchi AM, Delaini F, Guerini V, Ruggeri M, Rodeghiero F, Rambaldi A, Barbui T. (2008) Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Blood112(8): 3135-3137. IF 10.432
  1. Pancrazzi A, Guglielmelli P, Ponziani V, Bergamaschi G, Bosi A, Barosi G, Vannucchi AM. (2008) A sensitive detection method for MPLW515LorW515K mutation in chronic myeloproliferative disorders with LNA-modified probes and Real Time PCR. Journal of MolecularDiagnostics 10(5): 435-441.IF 3.643
  1. Guglielmelli P, Barosi G, Pieri L, Antonioli E, Bosi A, Vannucchi AM (2009) JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis. Haematologica 94(1):144-6. IF 5.978
  1. Guglielmelli P, Fatini C, Lenti M, Bosi A, Vannucchi AM (2009) JAK2V617F mutational screening in patients with retinal vein thrombosis or recurrent fetal loss. Thrombosis Research, 124:377-378 IF 2.449
  1. Vannucchi AM, Guglielmelli P, Pieri L, Antonioli E, Bosi A (2009) Treatment options for essential throimbocythemia and Polycythemia vera. Expert Reviews of Hematology, 2(1):41-55.
  1. Vannucchi AM, Guglielmelli P, Tefferi A (2009) Advances in understanding and management of myeloproliferative neoplasms. CA- A Cancer Journal for Clinicians 2009 May-Jun;59(3):171-91 IF 87.925
  1. Vannucchi AM, Masala G, Antonioli E, Susini MC, Guglielmelli P, Pieri L, Maggi L, Caini S, palli D, Bogani C, Ponziani V, Pancrazzi A, Annunziato F, Bosi A. (2009) Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. Cancer Epidemiology Biomarkers and Prevention 18(7):2068-73 IF 4.770
  1. Guglielmelli P, Barosi G, Specchia G, Rambaldi A, LoCoco F, Antonioli E, Pieri L, Pancrazzi A, Ponziani V, Delaini F, Longo G, Liso V, Bosi A, Barbui T, Vannucchi AM. (2009) Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617 mutated allele. Blood20;114(8):1477-83. IF 10.432
  1. Pieri L, Bogani C, Guglielmelli P, Zingariello M; Rana RA, Bosi A, Vannucchi AM (2009) The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera. Haematologica 2009 Nov;94(11):1537-45 IF 5.978
  1. Vannucchi AM, Guglielmelli P, Rambaldi A, Bogani C, Barbui T (2009) Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives. J Cell Mol Med. 2009 Aug;13(8A):1437-50. IF 5.114
  1. Carobbio A, Finazzi G, Antonioli E, Guglielmelli P, Vannucchi AM, Dellacasa CM, Salmoiraghi S, Delaini F, Rambaldi A, Barbui T (2009) JAK2V617F allele burden and thrombosis: a direct comparison in Essential Thrombocythemia and Polycythemia Vera. Experim Hematol, 37(9):1016-21 IF 3.203
  1. Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Guglielmelli P, Antonioli E, Alvarez-Larrán A, Rambaldi A, Finazzi G, Barosi G. (2010) Thrombosis in Primary Myelofibrosis: Incidence and Risk Factors. Blood Jan 28;115(4):778-82IF 10.432
  1. De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, Micò C, Tieghi A,Cacciola RR, Santoro C, Gerli G, Guglielmelli P, Pieri L, Scognamiglio F, Rodeghiero F, Pogliani EM, Finazzi G,Gugliotta L, Leone G, Barbui T (2010). Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia. American Journal of Hematology. 85(2):97-100 IF 2.126
  1. De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, Micò C, Tieghi A, Cacciola RR, Santoro C, Vianelli N, Guglielmelli P, Pieri L, Scognamiglio F, Cacciola E, Rodeghiero F, Pogliani EM, Finazzi G, Gugliotta L, Leone G, Barbui T. (2010) Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation. Annals of Hematology. 89(2):141-146 IF 2.454
  1. Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, Guglielmelli P, Pungolino E, Caramella M, Maffioli M, Pascutto C, Lazzarino M, Cazzola M, Tefferi A.. (2010) A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) . Blood. 115(9):1703-1708 IF 10.432
  1. Pieri L, Guglielmelli P, Vannucchi AM. Chronic myeloproliferative neoplasms: a collaborative approach Mediterr J Hematol Infect Dis. 2010 Jun 21;2(2):e2010017.
  1. Antonioli E., Carobbio A., Pieri L, Pancrazzi A, Guglielmelli P, Delaini F, Ponziani V, Bartalucci N, Tozzi L, Bosi A, Rambaldi A, Barbui T, Vannucchi A. (2010) Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with Polycythemia Vera or Essential Thrombocythemia.2010 Haematologica 95(8):1435-8 IF 5.978
  1. Verrucci M, Pancrazzi A, Aracil M, Martelli F, Guglielmelli P, Zingariello M, Ghinassi B, D’amore E, Jimeno J, Vannucchi AM, Migliaccio AR (2010). CXCR4-Indipendent rescue of the myeloproliferative defect of the Gata1 (low) Myelofibrosis mouse model by Aplidin ®. J. Cell Physiol. 2010 May 10. IF 4.313
  1. Tefferi A, Lasho TL, Abdel-Wahab O, Guglielmelli P, Patel J, Caramazza D, Pieli L, Finke CM, Kilpivaara O, Wadleigh M, Mai M, McClure RF, Gilliland DG, Levine RL, Pardanani A, Vannucchi AM.(2010) IDH1 and IDH2 mutation studies in 1473 patients with chronic-,fibrotic-or blast-phase Essential Thrombocythemia, Polycythemia Vera or Myelofibrosis. Leukemia 2010 2010 Jul;24(7):1302-9 IF 8.634
  1. Guglielmelli P, Biamonte F, Spolverini A, Pieri L, Isgrò A, Antonioli E, Pancrazzi A, Bosi A, Barosi G, Vannucchi AM (2010). Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary Myelofibrosis. Leukemia 2010 Aug;24(8):1533-7. IF 8.634
  1. Barosi G, Gattoni E, Guglielmelli P, Campanelli R, Facchetti F, Fisogni S, Goldberg J, Marchioli R, Hoffman R, Vannucchi AM; for the Myeloproliferative Research Consortium. (2010) Phase I/II study of single-agent bortezomib for the treatment of patients with Myelofibrosis. Clinical and biological effects of proteasome inhibition. Am. J. Hematol 2010 Aug;85(8):616-9. IF 2.126
  1. Rambaldi A, Della casa CM, Finazzi G, Carobbio A, Ferrari ML, Guglielmelli P, Gattoni E, Salmoiraghi S, Finazzi MC, DiTollo S, D’Urzo C, Vannucchi AM, Barosi G, Barbui T. (2010) A pilot study of the histone deacethylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. British Journal of Haematology 150(4):446-55. IF 4.597
  1. Vannucchi AM, Guglielmelli P (2010) Advances in understanding and management of polycythemia vera . Current opinion in Oncology. 2010 Nov;22(6):636-41IF 4.088
  1. Beer PA, Ortmann CA, Stegelmann F, Guglielmelli P, Reilly JT, Hasselbalch HC, Vannucchi AM, Dohner K, Green AR (2010) Molecular mechanisms associated with leukemic transformation of MPL-mutant myeloproliferative neoplasms. Haematologica In press IF 5.978
  1. Guglielmelli P, Vannucchi AM (2010) Recent advances in diagnosis and treatment of chronic myeloproliferative neoplasms. F1000 Med Rep. 2010 Feb 24;2. pii: 16.
  1. Rosti V, Bonetti E, Bergamaschi G, Campanelli R, Guglielmelli P, Maestri M, Magrini U, Massa M, Tinelli C, Viarengo G, Villani L, Primignani M, Vannucchi AM, Frassoni F, Barosi G; on behalf of the AGIMM Investigators.(2010) High Frequency of Endothelial Colony Forming Cells Marks a Non-Active Myeloproliferative Neoplasm with High Risk of Splanchnic Vein Thrombosis. PLoS One. 2010 Dec 9;5(12):e15277
  1. Barbui T, Carobbio A, Finazzi G, Vannucchi AM, Barosi G, Antonioli E, Guglielmelli P, Pancrazzi A, Salmoiraghi S, Zilio P, Ottomano C, Marchioli R, Cuccovillo I, Bottazzi B, Mantovani A, Rambaldi A (2010)Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and Pentraxin 3. Haematologica. 2011 Feb;96(2):315-8. Epub 2010 Dec 20. IF 5.978
  1. Desterke C, Bilhou-Nabéra C, Guerton B, Martinaud C, Tonetti C, Clay D, Guglielmelli P, Vannucchi A, Bordessoule D, Hasselbalch H, Dupriez B, Benzoubir N, Bourgeade MF, Pierre-Louis O, Lazar V, Vainchenker W, Bennaceur-Griscelli A, Gisslinger H, Giraudier S, Bousse-Kerdilès MC; on behalf of the French Intergroup of Myeloproliferative Disorders, the French INSERM, and the European EUMNET Networks on Myelofibrosis. (2011) FLT3-Mediated p38-MAPK Activation Participates in the Control of Megakaryopoiesis in Primary Myelofibrosis.Cancer Res. 2011 Apr 15;71(8):2901-2915. IF
  1. Guglielmelli P, Tozzi L, Bogani C, Iacobucci I, Ponziani V, Martinelli G, Bosi A, Vannucchi AM. (2011) Over-expression of microRNA-16-2 contributes to the abnormal erythropoiesis in polycythemia vera. Blood. 2011 Jun 23;117(25):6923-7n IF 10.432
  1. Klampfl T, Harutyunyan A, Berg T, Gisslinger B, Schalling M, Bagienski K, Olcaydu D, Passamonti F, Rumi E, Pietra D, Jäger R, Pieri L, Guglielmelli P, Iacobucci I, Martinelli G, Cazzola M, Vannucchi AM, Gisslinger H, Kralovics R. (2011) Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. Blood. 2011 Jul 7;118(1):167-76 IF 10.432
  1. Pardanani A, Guglielmelli P, Lasho TL, Pancrazzi A, Finke CM, Vannucchi AM, Tefferi A (2011) Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients. Leukemia. 2011 Jun 21. doi: 10.1038/leu.2011.161. IF 8.634
  1. Guglielmelli P, Barosi G, Rambaldi A, Marchioli R, Masciulli A, Tozzi L, Biamonte F, Bartalucci N, Gattoni E, Lupo ML, Finazzi G, Pancrazzi A, Antonioli E, Susini MC, Pieri L, Malevolti E, Usala E, Occhini U, Grossi A, Caglio S, Paratore S, Bosi A, Barbui T, Vannucchi AM.(2011) Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Blood. 2011 Aug 25;118(8):2069-76. Epub 2011 Jul 1 IF 10.432IF 10.432
  1. Guglielmelli P, Biamonte F, Score J, Hidalgo-Curtis C, Cervantes F, Maffioli M, Fanelli T, Ernst T, Winkelman N, Jones AV, Zoi K, Reiter A, Duncombe A, Villani L, Bosi A, Barosi G, Cross NC, Vannucchi AM. EZH2 mutational status predicts poor survival in myelofibrosis Blood. 2011 Nov 10;118(19):5227-34. Epub 2011 Sep 14. IF 10.432
  1. Puda A, Milosevic JD, Berg T, Klampfl T, Harutyunyan AS, Gisslinger B, Rumi E, Pietra D, Malcovati L, Elena C, Doubek M, Steurer M, Tosic N, Pavlovic S, Guglielmelli P, Pieri L, Vannucchi AM, Gisslinger H, Cazzola M, Kralovics R. Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. Am J Hematol. 2011 Nov 18. doi: 10.1002/ajh.22257. [Epub ahead of print] IF 3.576
  1. Bortoluzzi S, Bisognin A, Biasolo M, Guglielmelli P, Biamonte F, Norfo R, Manfredini R, Vannucchi AM.Characterisation and discovery of novel miRNAs and moRNAs in JAK2V617F mutated SET2 cells.Blood. 2012 Jan 5. [Epub ahead of print]IF 10.432

BOOK CHAPTERS

  1. Vannucchi AM, Villeval J-L, Wagner-Ballon O, Guglielmelli P, Migliaccio AR (2007) Animal models of myelofibrosis. In Conn PM, ed: Sourcebook of models for biomedical research. Human Press Inc, Totowa, NJ, USA pp 713-723.
  1. AM Vannucchi, P Guglielmelli.(2007) Regolazione dell’emopoiesi in A. Bosi (ed) “ Il sangue cordonale” SEE Firenze Editrice, pp41-63

16/01/2012